Nautilus Biotechnology (NASDAQ:NAUT) Cut to “Sell” at The Goldman Sachs Group

The Goldman Sachs Group lowered shares of Nautilus Biotechnology (NASDAQ:NAUT) from a neutral rating to a sell rating in a research report released on Thursday morning, MarketBeat reports. The Goldman Sachs Group currently has $1.75 price objective on the stock, down from their previous price objective of $2.25.

Nautilus Biotechnology Trading Up 11.5 %

NASDAQ NAUT opened at $2.14 on Thursday. The company has a 50-day moving average price of $2.56 and a two-hundred day moving average price of $2.57. Nautilus Biotechnology has a 52 week low of $1.88 and a 52 week high of $3.45. The stock has a market cap of $268.70 million, a price-to-earnings ratio of -3.82 and a beta of 1.14.

Nautilus Biotechnology (NASDAQ:NAUT) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.04. During the same period in the prior year, the business earned ($0.13) earnings per share. As a group, equities research analysts expect that Nautilus Biotechnology will post -0.57 earnings per share for the current fiscal year.

Insider Activity at Nautilus Biotechnology

In related news, VP Mary E. Godwin sold 35,000 shares of the stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $2.85, for a total value of $99,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 40.50% of the company’s stock.

Institutional Trading of Nautilus Biotechnology

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Barclays PLC boosted its holdings in shares of Nautilus Biotechnology by 79.6% in the third quarter. Barclays PLC now owns 106,174 shares of the company’s stock valued at $303,000 after acquiring an additional 47,059 shares in the last quarter. Wexford Capital LP boosted its stake in Nautilus Biotechnology by 9.6% during the 3rd quarter. Wexford Capital LP now owns 228,350 shares of the company’s stock valued at $651,000 after purchasing an additional 20,000 shares in the last quarter. MetLife Investment Management LLC acquired a new position in shares of Nautilus Biotechnology during the 3rd quarter valued at $87,000. The Manufacturers Life Insurance Company acquired a new position in shares of Nautilus Biotechnology during the 3rd quarter valued at $67,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Nautilus Biotechnology by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 24,121 shares of the company’s stock worth $69,000 after buying an additional 9,404 shares in the last quarter. 50.71% of the stock is currently owned by institutional investors.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.